CN114341137A - 二氢嘧啶衍生物及其用途 - Google Patents
二氢嘧啶衍生物及其用途 Download PDFInfo
- Publication number
- CN114341137A CN114341137A CN202080057115.8A CN202080057115A CN114341137A CN 114341137 A CN114341137 A CN 114341137A CN 202080057115 A CN202080057115 A CN 202080057115A CN 114341137 A CN114341137 A CN 114341137A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkylene
- group
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
通式(I)的二氢嘧啶类衍生物，它们可用于治疗和预防乙型肝炎病毒感染。还涉及含有通式(I)化合物的药物组合物，及其用于治疗和预防乙型肝炎病毒感染的用途。
Description
PCT国内申请，说明书已公开。
Claims (26)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910758274 | 2019-08-16 | ||
| CN201910758274X | 2019-08-16 | ||
| CN2020108077914 | 2020-08-12 | ||
| CN202010807791 | 2020-08-12 | ||
| PCT/CN2020/109140 WO2021031997A1 (zh) | 2019-08-16 | 2020-08-14 | 二氢嘧啶衍生物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114341137A true CN114341137A (zh) | 2022-04-12 |
| CN114341137B CN114341137B (zh) | 2024-09-20 |
Family
ID=74659909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080057115.8A Active CN114341137B (zh) | 2019-08-16 | 2020-08-14 | 二氢嘧啶衍生物及其用途 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN114341137B (zh) |
| TW (1) | TW202115079A (zh) |
| WO (1) | WO2021031997A1 (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015180631A1 (zh) * | 2014-05-30 | 2015-12-03 | 南京明德新药研发股份有限公司 | 作为hbv抑制剂的二氢嘧啶并环衍生物 |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109843296A (zh) * | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| WO2019113173A1 (en) * | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019113175A1 (en) * | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2794639T3 (es) * | 2015-11-04 | 2020-11-18 | Qilu Pharmaceutical Co Ltd | Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido |
| WO2020001592A1 (zh) * | 2018-06-28 | 2020-01-02 | 河南天晟泰丰医药科技有限公司 | 二氢嘧啶衍生物及其用途 |
-
2020
- 2020-08-14 CN CN202080057115.8A patent/CN114341137B/zh active Active
- 2020-08-14 WO PCT/CN2020/109140 patent/WO2021031997A1/zh not_active Ceased
- 2020-08-17 TW TW109127919A patent/TW202115079A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015180631A1 (zh) * | 2014-05-30 | 2015-12-03 | 南京明德新药研发股份有限公司 | 作为hbv抑制剂的二氢嘧啶并环衍生物 |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109843296A (zh) * | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| WO2019113173A1 (en) * | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019113175A1 (en) * | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021031997A1 (zh) | 2021-02-25 |
| CN114341137B (zh) | 2024-09-20 |
| TW202115079A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2745431C1 (ru) | Гетероарильное производное пиперазина, способ его получения и применение в медицине | |
| RU2655914C9 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| CN106459009B (zh) | 丙肝病毒抑制剂及其制药用途 | |
| CA3017020A1 (en) | Hepatitis b antiviral agents | |
| WO2016161268A1 (en) | Hepatitis b antviral agents | |
| EA004987B1 (ru) | Производные пурина | |
| WO2020233641A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| CN111018891B (zh) | 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类 | |
| CN113698390B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| TW202311260A (zh) | 含有亞磺醯亞胺基的atr抑制劑化合物 | |
| WO2015101183A1 (zh) | 尿嘧啶核苷酸类似物及其制备方法和应用 | |
| CA3190495A1 (en) | Compounds, compositions and methods | |
| CN112469716B (zh) | 二氢嘧啶衍生物及其用途 | |
| WO2021078274A1 (zh) | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 | |
| WO2024222677A1 (zh) | Wrn抑制剂 | |
| JP2019535644A (ja) | ジヒドロピリミジン化合物並びにその調製方法及び使用 | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| JP2023145644A (ja) | ジヒドロイソキノリン系化合物 | |
| WO2022242725A1 (zh) | 一类新型蛋白降解剂及其应用 | |
| WO2024067744A1 (zh) | 杂环取代喹唑啉及其制备方法和应用 | |
| CN113045569B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| CN111718332B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| WO2021218997A1 (zh) | 取代的氮杂五元环类化合物及其在药物中的应用 | |
| CN114341137B (zh) | 二氢嘧啶衍生物及其用途 | |
| TWI847445B (zh) | 一種噠嗪類化合物、其藥物組合物及應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Rooms 1506 and 1515, economic foundation building of the headquarters of Lhasa Economic and Technological Development Zone, 850000 Tibet Autonomous Region Patentee after: Xizang Tiansheng Taifeng Pharmaceutical Co.,Ltd. Country or region after: China Address before: Rooms 1506 and 1515, economic foundation building of the headquarters of Lhasa Economic and Technological Development Zone, 850000 Tibet Autonomous Region Patentee before: Tibet Tiansheng Taifeng Pharmaceutical Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20251029 Address after: 310000 Zhejiang Province, Hangzhou City, Gushu District, Dongxin Street, Haozhang Building No. 1, Room 1106 Patentee after: Hangzhou Tiansheng Taifeng Pharmaceutical Co.,Ltd. Country or region after: China Address before: Rooms 1506 and 1515, economic foundation building of the headquarters of Lhasa Economic and Technological Development Zone, 850000 Tibet Autonomous Region Patentee before: Xizang Tiansheng Taifeng Pharmaceutical Co.,Ltd. Country or region before: China |